AlYamany R, Kharfan-Dabaja MA, Hamadani M, Alshaibani A, Aljurf M. The Evolution of Our Understanding of Immunoproliferative Small Intestinal Disease (IPSID) over Time.
Curr Oncol 2022;
29:3759-3769. [PMID:
35621691 PMCID:
PMC9139652 DOI:
10.3390/curroncol29050301]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Revised: 05/14/2022] [Accepted: 05/18/2022] [Indexed: 11/16/2022] Open
Abstract
Immunoproliferative small intestinal disease (IPSID) is an uncommon disease with a higher prevalence in the developing world. IPSID diagnosis relies mainly on a tissue biopsy and a high index of suspicion. Treatment options are variable; however, they mainly include anthracycline-based chemotherapy with or without antibiotics in advanced stages. Because of the paucity of IPSID, our perception of the disease remains narrow, and investigating the optimal lines of therapy and prevention without a complete comprehension of the disease is challenging. In our review, we explore the expansion of knowledge about IPSID, which has been developing over the years, to help increase the detection of IPISD cases and further research the most appropriate lines of therapy and prevention.
Collapse